583 results on '"Wexler, Ruth R."'
Search Results
2. Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction
3. Discussion of talks from the symposium: Factor X: From thrombokinase to oral anti-coagulants and beyond
4. From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis
5. Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure
6. Phthalazinone-based lactams and cyclic ureas as ROCK2 selective inhibitors
7. Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group
8. Design and preparation of N-linked hydroxypyridine-based APJ agonists
9. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4
10. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
11. Abstract 13794: An Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986141, Prevents Aeterial Thrombosis With Low Bleeding Liability in Cynomolgus Monkeys
12. In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa
13. Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists
14. Synthesis of tertiary carbinamines
15. Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure
16. Cardiovascular and Metabolic Diseases: 50 Years of Progress
17. Identification of 6-hydroxy-5-phenyl sulfonylpyrimidin-4(1H)-one APJ receptor agonists
18. Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists
19. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
20. Medicinal Chemistry of Angiotensin II Antagonists
21. Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO)
22. Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate
23. Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies
24. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors
25. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
26. Discovery and SAR of aryl hydroxy pyrimidinones as potent small molecule agonists of the GPCR APJ
27. Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa
28. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits
29. Benzothiazole-based compounds as potent endothelial lipase inhibitors
30. Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability
31. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase
32. Case History
33. Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure.
34. Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase
35. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species
36. Identification of Reversible Small Molecule Inhibitors of Endothelial Lipase (EL) That Demonstrate HDL-C Increase In Vivo
37. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
38. Corrigendum to “Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase” [Bioorg. Med. Chem. Lett. 29 (2019) 1918–1921]
39. Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.
40. Chapter 10. Antiplatelet therapies
41. Chapter 9. Anticoagulants: Thrombin and Factor Xa Inhibitors
42. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors
43. Antiplatelet agents
44. Macrocyclic factor XIa inhibitors
45. Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy
46. Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor
47. Nonpeptide Angiotensin II Receptor Antagonist: Losartan
48. Contributors to Volume 13
49. Discovery and synthesis of tetrahydropyrimidinedione-4-carboxamides as endothelial lipase inhibitors
50. Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.